Pharmaceutical Executive-06-01-2011

Issue PDF
Pharmaceutical Executive

June 01, 2011

Emerging Pharma Leaders 2011

Pharmaceutical Executive
Columns

June 01, 2011

FDA's opiod REMS implies there is still value in industry-sponsored CME

Pharmaceutical Executive

The payoff is superior performance in key areas such as clinical trials

Pharmaceutical Executive

June 01, 2011

Carefully crafting your brand's positioning could ensure that you'll not just win the sprint, but also the marathon

Pharmaceutical Executive
Features

June 01, 2011

With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.

Pharmaceutical Executive

NicVAX is trying to buck the trend of smoking-cessation products' high failure rate

Pharmaceutical Executive

Pharma company communicators must steer the conversation about vaccines to the ultimate goal-preventing disease

Columns
Pharmaceutical Executive

June 01, 2011

Why has the EU still not managed to update its rules on information about medicines?

Pharmaceutical Executive
Features

June 01, 2011

Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships

Columns
Pharmaceutical Executive

June 01, 2011

NeHC's new Consumer Consortium is promoting a new stakeholder agenda to improve patient knowledge

Pharmaceutical Executive
Features

June 01, 2011

Meet 2011's Emerging Pharma Leaders-Can these 30 trendsetters build competitive scale from scarcity?

Pharmaceutical Executive

Creating and managing expectations is the most basic rule of marketing

Pharmaceutical Executive

Successful negotiations require a willingness to take risks and an ability to adapt

Pharmaceutical Executive
Columns

June 01, 2011

Patent expiries are inevitable, but brand teams should look to graduate the sales curve

Columns
Pharmaceutical Executive

June 01, 2011

What do our genetics tell us about our predisposition to certain diseases?

Pharmaceutical Executive

A vaccination against addiction could open up a whole new category

Pharmaceutical Executive

To decide on a course of treatment, patients need to be told the truth straight up

Pharmaceutical Executive
From the Editor

June 01, 2011

Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term

Pharmaceutical Executive

The three components of the NicVAX launch challenge

Pharmaceutical Executive

With a first-in-class compound marketers can potentially leverage long-lasting market advantages

Pharmaceutical Executive

Suggestions for testing new ways of addressing difficult issues of risk